Abstracts 2026

Abstract Code: IUC26509-87 Real-World Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma Zeb 1 (1) Heartland Hospital,...

IUC26689-96

Abstract Code: IUC26689-96 Presentation, Management, and Preliminary Outcomes of Penile Cancer in a Latin American Referral CohortR.S. Serna Sejas 1, C.L. Tsou 2, R....

IUC26687-94

Abstract Code: IUC26687-94 Clinical and Pathologic Outcomes of Resection of Thoracic Residual Masses in Germ Cell Tumors Jubran 1, E. Erbetta 1, V. Verzeletti 2, A. Di...

IUC26681-88

Abstract Code: IUC26681-88 Carboplatin AUC 10 in Good-Prognosis Metastatic Seminoma: A Portuguese Real-World Experience Figueiredo 1, J. Pedro Barata 1, S. Magno 1, F. Vaz...

IUC26677-93

Abstract Code: IUC26677-93 Divergent Outcomes In Mediastinal Seminoma And Nonseminomatous Germ Cell Tumors: A Real-World Experience Hota 1, M.L. Konatam 1, R. Chennamaneni...

IUC26668-93

Abstract Code: IUC26668-93 Clinicopathological Features, Treatment Patterns and Outcomes in Small Cell Carcinoma of the Prostate and Urinary Bladder: A Retrospective Study...

IUC26664-89

Abstract Code: IUC26664-89 De-escalated management of stage I seminoma: three decades of real-world outcomes M.P. Juan Gonzalez 1, C. Martinez Martinez 1, A.J. Montalban...

IUC26561-85

Abstract Code: IUC26561-85 Real-World Outcomes of Testicular Germ Cell Tumors in Pakistan: A Retrospective Study from A Tertiary Care Center Sundas 1, S.B. Ahmed 2, M....

IUC26510-79

Abstract Code: IUC26510-79 Spondias Mombin Leaf Extract show selective toxicity to testicular cancer cells lines in vitro Proudman 1, P. Savage 1 (1) Cardiff University -...

IUC26498-94

Abstract Code: IUC26498-94 Diagnostic Pathway Delay in Penile Squamous Cell Carcinoma: a UK Regional Cohort Study J.M. Haider 1 (1) St George's University Hospitals NHS...

IUC26700-80

Abstract Code: IUC26700-80 Outcomes of dual immunotherapy versus other first line treatments for metastatic renal carcinoma Woods 1, S. Growcott 1, A. Gee 1 (1) Royal...

IUC26699-97

Abstract Code: IUC26699-97 Who Gets Left Out? The Real-World Eligibility Gap in Landmark Metastatic Renal Cell Carcinoma Trials Zeb 1 (1) university Hospital Birmingham -...

IUC26697-95

Abstract Code: IUC26697-95 First Line Tyrosine Kinase Inhibitors (TKIs) in metastatic Renal Cell Cancer (mRCC)- A regional cancer Centre experience. Gul 1, O. Oghenevwede 2, E....

IUC26695-93

Abstract Code: IUC26695-93 Real-world Outcomes of First-line Immune Checkpoint Inhibitor–Tyrosine Kinase Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma:...

IUC26694-92

Abstract Code: IUC26694-92 Stereotactic Body Radiotherapy and Immunotherapy for Metastatic Renal Cell Carcinoma Croatian Uro-Oncology Network Experience Brcic 1, J. Murgic...

IUC26693-91

Abstract Code: IUC26693-91 CHOLESTEROL HOMEOSTASIS AND IMMUNE-INFLAMMATORY PROFILES IN PATIENTS WITH mRCC RECEIVING IMMUNOTHERAPY Tuttobene 1, M. Maffezzoli 2, G. Leali 1,...

IUC26691-89

Abstract Code: IUC26691-89 Real-World Outcomes of Delayed Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Following Systemic Therapy: A Tertiary Centre...

IUC26690-88

Abstract Code: IUC26690-88 Cannabinoid Receptor Profiling Reveals a Low CB1 and High CB2 signature in Clear Cell Renal Cell Carcinoma Singh 1, S. Pattanaik 2, R.S....

IUC26686-93

Abstract Code: IUC26686-93 Synergistic potential of cabozantinib and radiotherapy in advanced renal cell carcinoma by site of irradiation Di Costanzo 1, A. Bertocchi 2,...

IUC26684-91

Abstract Code: IUC26684-91 Real world outcomes of immune checkpoint inhibitors in metastatic renal cell cancer(mRCC) from a tertiary care cancer centre in South India M.S....

IUC26682-89

Abstract Code: IUC26682-89 Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world...

IUC26678-94

Abstract Code: IUC26678-94 Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33 Peretto 1, S.E. Rebuzzi 2, E. Verzoni 3, S. Buti 4, M. Di Napoli 5, C....

IUC26672-88

Abstract Code: IUC26672-88 Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33) Aspden 1, D. Bimbatti 2, A. Dalla Volta 3, G....

IUC26671-87

Abstract Code: IUC26671-87 Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026 Buchanan 1, G. Clements 1, C. Forde 1, A. Clayton 1 (1)...

IUC26666-91

Abstract Code: IUC26666-91 Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor...

IUC26658-92

Abstract Code: IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and...

IUC26657-91

Abstract Code: IUC26657-91 Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study. Zinelli Ronzoni 1, M. Maffezzoli 1, E. Lai 2,...

IUC26628-89

Abstract Code: IUC26628-89 Real-World Outcomes of Adjuvant Pembrolizumab in Renal Cell Carcinoma: A Single-Centre Experience Okuma 1, C. Nwankwo 1, M. Cortez 1, M....

IUC26562-86

Abstract Code: IUC26562-86 Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis...

IUC26559-92

Abstract Code: IUC26559-92 Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Evidence from an Immunotherapy-Inaccessible Cohort...

IUC25693-90

Abstract Code: IUC25693-90 Real-world effectiveness of pembrolizumab plus axitinib in metastatic renal cell carcinoma in Panama Pinto 1, A. Cardenas 2 (1) Head of oncology...

IUC25517-85

Abstract Code: IUC25517-85 Title: First‑line TKI, ipilimumab–nivolumab, and lenvatinib–pembrolizumab in metastatic non–clear cell RCC: real‑world survival across two UK...

IUC25516-84

Abstract Code: IUC25516-84 Non clear renal cell carcinoma: metastatic patterns and survival from a real‑world cohort Maamoun 1, M. Al-Essa 2, I. Pedley 3, A. Azzabi 3, S....

IUC26688-95

Abstract Code: IUC26688-95 S100A9 Identifies Distinct Circulating Myeloid Cell Subsets in Metastatic Prostate Cancer Iglesias 1, M.F. Guerra 2, R. Hinojosa Altamirano 3,...

IUC26679-95

Abstract Code: IUC26679-95 A pilot study of the implementation of the G8 frailty assessment in oncology clinics for patients with newly diagnosed metastatic hormone...

IUC26675-91

Abstract Code: IUC26675-91 Patterns of de novo metastatic prostate cancer presentation: clinical, biological, and topographic characteristics at Mohammed VI University...

IUC26673-89

Abstract Code: IUC26673-89 Reducing adverse outcomes following local anaesthetic trans-perineal prostate biopsies Moshtael 1, M. Johnston 1, G. Crowther 1, J. Brewin 1 (1)...

IUC26669-94

Abstract Code: IUC26669-94 The LDR BURST Trial: A Randomised Comparison of Toxicity Outcomes following LDR Brachytherapy vs 5-Fraction SBRT with a Rectal Spacer for...

IUC26667-92

Abstract Code: IUC26667-92 Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ±...

IUC26665-90

Abstract Code: IUC26665-90 Global inequalities in prostate cancer incidence and mortality: an ecological analysis Hosseini 1, Y. Vaez-Gharamaleki 1, A. Motamedi 1 (1)...

IUC26663-88

Abstract Code: IUC26663-88 Real-world ARASENS triplet therapy in high-volume mHSPC: a single-centre cohortM.P. Juan Gonzalez 1, C. Martinez Martinez 1, A.J. Montalban...

IUC26662-87

Abstract Code: IUC26662-87 Ultra-low PSA as a real-world indicator of androgen receptor pathway inhibitors (ARPI) treatment response in metastatic prostate cancer Ghigeanu...

IUC26661-86

Abstract Code: IUC26661-86 Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide - A...

IUC26659-93

Abstract Code: IUC26659-93 Transdermal Estradiol as an Alternative to LHRH Agonists in Prostate Cancer Management Khanna 1, S. Debra 1, D. Sethi 1, M. Abdel-Missih 1 (1)...

IUC26655-89

Abstract Code: IUC26655-89 Pretreatment Hemoglobin-Albumin-Lymphocyte-Platelet Score, Dosimetry, and Acute Toxicity After Definitive Prostate Radiotherapy: Interim...

IUC26651-85

Abstract Code: IUC26651-85 AI-assisted Biparametric vs Multiparametric MRI for Clinically Significant Prostate Cancer Tiwari 1, K. Bhagat 2, U. Khan 3, J.K. Tan 4, D....

IUC26648-91

Abstract Code: IUC26648-91 Cost-effectiveness of Intensity-Modulated Radiation Therapy versus Robot-Assisted Radical Prostatectomy in Patients with Prostate Cancer: A...

IUC26645-88

Abstract Code: IUC26645-88 Challenges of AI in Surgical Planning for Radical Prostatectomy: Barriers and Progress Rajaee Rizi 1, M.S. Jamadi 2 (1) Endocrine and Metabolism...

IUC26615-85

Abstract Code: IUC26615-85 Are PSMA (Prostate-Specific Membrane Antigen) PET-CT scans in our unit requested according to NHS England Commissioning Criteria on prostate...

IUC26597-94

Abstract Code: IUC26597-94 Longitudinal Trends in Androgen Receptor Pathway Inhibitor Prescribing for Metastatic Prostate Cancer in England Between 2013-2025 Using...

IUC26567-91

Abstract Code: IUC26567-91 A Novel, Cost-Reducing Hyaluronic Acid and Lipiodol Composite for Perirectal Tissue Spacing in Prostate Cancer: Safety and efficacy Elgarhy 1,...

IUC26557-90

Abstract Code: IUC26557-90 Retrospective Review of a Prostate Brachytherapy Case cohort Conducted in Botswana: Clinical Outcomes and Adverse Events Bunga 1, B. Molatodi...

IUC25511-79

Abstracts 2026, Miscellaneous 26

Abstract Code: IUC25511-79 Prostate volume changes during longer fractionated and ultra-hypofractionated MR-guided adaptive radiotherapy leveraging the MOMENTUM registry Cooper...

IUC26660-85

Abstract Code: IUC26660-85 Severe immune checkpoint inhibitor toxicity drives additional costs Khanjra 1, M. Emmerich 2, J. Larkin 1, Z. Tippu 1, S. Turajlic 3 (1) Skin...

IUC25592-88

Abstracts 2026, Miscellaneous 26

Abstract Code: IUC25592-88 Exploring the Use of AI-Enhanced Virtual Reality in Teaching and Evaluating Communication Skills in Urology: A Pilot Study Saad 1 (1) Newham...

IUC26698-96

Abstract Code: IUC26698-96 Durvalumab + BCG therapy in BCG-naïve, high-risk NMIBC: efficacy and safety analyses from POTOMAC Hussain 1, N. Shore 2, H. Nishiyama 3, J....

IUC26696-94

Abstract Code: IUC26696-94 Enfortumab Vedotin Plus Pembrolizumab Outcomes in Advanced Urothelial Cancer: Real-World Data Peroos 1, A. Saeed 1, S. Jenkinson 1, A. Clifford...

IUC26692-90

Abstract Code: IUC26692-90 Benchmarking Artificial Intelligence Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder...

IUC26685-92

Abstract Code: IUC26685-92 Characterizing the Immune Landscape of Non-Muscle-Invasive Bladder Cancer Fornarini 1, D. Fenoglio 2, F. Ferrera 2, L. Camporesi 2, A. Lagazio...

IUC26683-90

Abstract Code: IUC26683-90 BlAdder Cancer Circulating biomarkers after treatment exposUre for early detection of relapse: The BACCUS study Mills 1, A. Bertocchi 2, P....

IUC26680-87

Abstract Code: IUC26680-87 Reducing Infection Risk During Intravesical BCG Through Nitrofurantoin Prophylaxis and Patient Education Obat 1, A. Njambi 2, M. Osoo 1, H....

IUC26676-92

Abstract Code: IUC26676-92 HER2-low expression and cell proliferation in urinary bladder carcinomas Dumitru 1, M. Hortopan 2, M. Mihaila 3, C.M. Hotnog 3, L.I. Brasoveanu...

IUC26670-86

Abstract Code: IUC26670-86 Radiotherapy Access Gaps for Bladder and Prostate Cancer in East Java, Indonesia Harsono 1, G.B. Prajogi 2 (1) Kabupaten Kediri General...

IUC26652-86

Abstract Code: IUC26652-86 Clinical impact and safety profile of Enfortumab-vedotin: evaluate the efficacy and safety outcomes obtained in patients diagnosed with...

IUC26600-79

Abstract Code: IUC26600-79 ‘STATE-OF-THE-NATION’ STUDY: UNDERSTANDING NHS TREATMENT PATHWAY TO ADVANCE HR NMIBC PATIENT CARE in the UK (SPAN UK) Aning 1, J. Catto 2, R....

IUC26590-87

Abstract Code: IUC26590-87 Outcomes of Novel Systemic Therapies in Advanced Upper Tract Urothelial Carcinoma: A systematic Review and Meta-Analysis D'arienzo 1, D....

IUC26589-95

Abstract Code: IUC26589-95 First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and...

IUC26569-93

Abstract Code: IUC26569-93 Enfortumab-Vedotin with Pembrolizumab vs platinum-based therapy for advanced urothelial cancer in Oxford. Al Kharusi 1, S. San Ti 1, A....

IUC26529-89

Abstract Code: IUC26529-89 Sex Differences in Enfortumab Vedotin Efficacy and NECTIN-4 Levels in Metastatic Urothelial Cancer Taha 1, A. Alpert 2, A. Rizzo 3, F....

IUC25980-89

Abstract Code: IUC25980-89 Impact of Ureteroscopy on Diagnostic Pathways and Radical Nephroureterectomy Outcomes in Upper Tract Urothelial Carcinoma Maleki 1, L.F.C. Yu 1,...

IUC25722-83

Abstract Code: IUC25722-83 Bladder Cancer in Young Women: Clinicopathological Features and Risk Factors from a Multi-Center Retrospective Study Saberi 1, Y. Ahmad 2, N....

IUC25665-89

Abstract Code: IUC25665-89 BK Virus Associated Urothelial Carcinoma – A Regional Cohort of Kidney Transplant Recipients Beetge 1, L. Ribeiro 2, C. Horsfield 2, R. Zakri 2,...

IUC25664-88

Abstract Code: IUC25664-88 Whole-Organ Radiotherapy in the Era of Poor Anatomical Resolution: Evidence from a Population-Based Bladder Cancer Registry (Sri Lanka,...

IUC26674-90